IDO2 and cancer: Recently, the cancer treatment paradigm has evolved rapidly with the approval of several checkpoint inhibitors, which revealed that immunotherapy had have exhibited superior efficacy to chemotherapy alone.[1, 2] Among the immune checkpoint blockers, an inhibitor of indoleamine 2,3‐dioxygenase has emerged as a promising therapeutic agent for cancer treatment.